RealFeedApp FDA approved FYB206 by Q3 2027
The FDA accepted FYB206 for potential approval in Q3 2027, yet branded manufacturers leverage PBM deals to maintain market dominance.
- Field
- drugs and trials
- What they did
- The FDA approved the first publicly announced application for a Keytruda biosimilar (FYB206), which could receive approval as early as the third quarter of 2027.
- Why it matters
- This will open the door to competition for the world's bestselling cancer drug, which generated $31.7 billion in revenue for Merck & Co. in 2025.
#biosimilars#keytruda#fda#pharmaceutical supply chain#fyb206
